Testing a new combination treatment for moderate to severe ulcerative colitis

This study is testing whether LY4268989, a new oral medication, works better when combined with mirikizumab (an existing treatment given by IV infusion and then injections under the skin) compared to mirikizumab alone. The trial involves adults with moderate to severe ulcerative colitis who have not responded well to, or cannot tolerate, other treatments. Researchers want to see if this new combination approach can help control symptoms and reduce inflammation more effectively.

Ulcerative colitis is a serious inflammatory bowel condition that causes ongoing symptoms even with current treatments. Some patients don't respond well enough to existing medications, and doctors need new options to help these patients achieve better control of their disease.